Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risk-adapted use of dose-dense chemotherapy in poor prognosis non-seminomatous germ cell tumors
2005-001072-13Phase 3Completed
- Sponsor
- Unicancer
- Start
- Sep 2005
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of bleomycin, etoposide, cisplatin, paclitaxel, oxaliplatin and 1 more in non-seminomatous germ cell tumor (NSGCT) (2 arms), sponsored by Unicancer. Primary endpoint: Progression-free survival. Started Sep 2005; status: completed.
02
Drugs
bleomycinetoposidecisplatinpaclitaxeloxaliplatin
03
Conditions
non-seminomatous germ cell tumor (NSGCT)
Beyond the preview
Go deeper on 2005-001072-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001072-13.